Lupin launches Merzee capsules in US market

Lupin launches Merzee capsules in US market

Lupin Limited has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC (Slayback). Slayback had earlier launched this product in the US. Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International Limited.
 
Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla) had estimated annual sales of US$ 90 million in the US